参苓白术散通过改善肠道微生物群、炎症和免疫反应增强头孢克肟对儿童的抗肺炎作用。
Shen-Ling-Bai-Zhu-San Enhances the Antipneumonia Effect of Cefixime in Children by Ameliorating Gut Microflora, Inflammation, and Immune Response.
作者信息
Feng Jinli, Zhang Cheng, Chen Houjun, Chen Ziliang, Chen Yongfeng, He Degen, Pan Qianyi, Zhou Yongmao, Chen Zhaoyang, Zhuang Xiaozheng
机构信息
Emergency Department, Zhongshan Hospital, Guangzhou University of Chinese Medicine, Zhongshan, Guangdong 528401, China.
Clinical Laboratory, Zhongshan Hospital, Guangzhou University of Chinese Medicine, Zhongshan, Guangdong 528401, China.
出版信息
Evid Based Complement Alternat Med. 2022 Sep 7;2022:7752426. doi: 10.1155/2022/7752426. eCollection 2022.
OBJECTIVE
Shen-Ling-Bai-Zhu-San (SLBZS) is used for treating gastrointestinal disorders. However, the role of SLBZS in treating pneumonia in children is still unclear.
METHODS
In this study, children (≥2 and <9 years) with pneumonia were treated with 0.1 g cefixime (cefixime group) or 0.1 g cefixime + 9 g SLBZS (SLBZS + cefixime). The drugs were administered twice daily for 10 days. The therapeutic effects of the two groups were compared. The white blood cell (WBC), neutrophil, and lymphocyte counts; neutrophil-lymphocyte ratio (NLR); serum inflammatory factor levels; and gut microflora were assessed.
RESULTS
The clinical efficacy of SLBZS + cefixime treatment of pneumonia in children was higher than that of cefixime alone (93.3% 86.7%). Both cefixime and SLBZS + cefixime treatments decreased the area of pulmonary inflammatory lesions, reduced white blood cell and neutrophil counts, neutrophil-lymphocyte ratio, inflammation, and increased lymphocyte count in children with pneumonia compared with those before treatment. Moreover, SLBZS enhanced the anti-inflammation and immunity-enhancing effects of cefixime in children with pneumonia. SLBZS + cefixime treatment decreased , , , and counts and increased and counts. Compared with the cefixime treatment group, the count of the six bacterial strains in the SLBZS + cefixime treatment group was closer to the normal level.
CONCLUSION
SLBZS enhanced the antipneumonia effect of cefixime in children with pneumonia by ameliorating gut microflora, inflammation, and immune response.
目的
参苓白术散（SLBZS）用于治疗胃肠道疾病。然而，SLBZS在治疗儿童肺炎中的作用仍不明确。
方法
在本研究中，肺炎患儿（≥2岁且<9岁）接受0.1 g头孢克肟治疗（头孢克肟组）或0.1 g头孢克肟+9 g SLBZS治疗（SLBZS+头孢克肟组）。药物每日给药两次，持续10天。比较两组的治疗效果。评估白细胞（WBC）、中性粒细胞和淋巴细胞计数；中性粒细胞与淋巴细胞比值（NLR）；血清炎症因子水平；以及肠道微生物群。
结果
SLBZS联合头孢克肟治疗儿童肺炎临床疗效高于单用头孢克肟（93.3%对86.7%）。与治疗前相比，头孢克肟和SLBZS联合头孢克肟治疗均减小了肺炎患儿肺部炎症病变面积，降低了白细胞和中性粒细胞计数、中性粒细胞与淋巴细胞比值、炎症水平，并增加了淋巴细胞计数。此外，SLBZS增强了头孢克肟对肺炎患儿的抗炎和免疫增强作用。SLBZS联合头孢克肟治疗降低了 、 、 、 计数，并增加了 、 计数。与头孢克肟治疗组相比，SLBZS联合头孢克肟治疗组6种菌株的计数更接近正常水平。
结论
SLBZS通过改善肠道微生物群、炎症和免疫反应，增强了头孢克肟对儿童肺炎的抗肺炎作用。
Zotero 插件